The Effect of Acipimox on GLP-1 Secretion in Healthy Subjects: a Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Levels of GLP-1 in plasma
研究概览
简要总结
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus). Recently it was found, that levels of GLP-1 are increased in response to acipimox. The hypothesis is that G protein coupled receptors on enteroendocrine L cells bind acipimox and thereby induce GLP-1 secretion.
In a controlled, open, randomized experiment, eight healthy, overweight men will be studied on an intervention day, where they receive acipimox, and on a control day. The study day includes an OGTT (oral glucose tolerance test), blood samples before and after the OGTT and a biopsy from adipose tissue.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Adult men
- •BMI 25-35
排除标准
- •Known DM2
- •Receiving hypolipidemic drugs
研究组 & 干预措施
Acipimox
Administration of acipimox 250 mg p.o.
干预措施: Acipimox (Drug)
结局指标
主要结局
Levels of GLP-1 in plasma
时间窗: 9 months
次要结局
- Lipolytic activity in adipose tissue by measuring FFA (free fatty acid) levels(9 months)
- Insulin sensitivity by measuring blood glucose after an OGTT(5 months)